Whilst we ponder who is buying and selling I personally like the fact that Hedge Funds and Institutional Investors appear to have been accumulating. This may also explain the presence of all of the bots but imo overtime it is a good thing.
Maxim Group Reiterates “Buy” Rating for Kazia Therapeutics (NASDAQ:KZIA)
Maxim Group reissued their buy rating on shares of Kazia Therapeutics (NASDAQ:KZIA) in a research note published on Friday, Price Targets.com reports. Maxim Group currently has a $18.00 price target on the stock.
Shares of NASDAQ KZIA opened at $7.92 on Friday. The business has a 50-day moving average of $10.83 and a 200-day moving average of $10.17. Kazia Therapeutics has a fifty-two week low of $7.70 and a fifty-two week high of $14.89.
Hedge funds and other institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC grew its holdings in shares of Kazia Therapeutics by 12.1% in the 2nd quarter. SG Americas Securities LLC now owns 44,398 shares of the company’s stock valued at $438,000 after acquiring an additional 4,782 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Kazia Therapeutics by 188.2% in the 2nd quarter. Renaissance Technologies LLC now owns 65,823 shares of the company’s stock valued at $649,000 after acquiring an additional 42,983 shares in the last quarter. Morgan Stanley grew its holdings in shares of Kazia Therapeutics by 28.5% in the 1st quarter. Morgan Stanley now owns 230,801 shares of the company’s stock valued at $2,862,000 after acquiring an additional 51,201 shares in the last quarter. Citadel Advisors LLC bought a new position in shares of Kazia Therapeutics in the 2nd quarter valued at about $126,000. Finally, Total Clarity Wealth Management Inc. acquired a new stake in Kazia Therapeutics in the 3rd quarter valued at about $54,000. Institutional investors own 3.29% of the company’s stock.
KZA Price at posting:
$1.17 Sentiment: Hold Disclosure: Held
